John J. Tentler

Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells.

The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression.

ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells.

Structural and functional analysis of the differential effects of c-Jun and v-Jun on prolactin gene expression.

Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.

Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.

Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.

Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism.

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

Patient-derived tumour xenografts as models for oncology drug development.

ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.

Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1.

Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.

Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.

Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.

Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.

p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.